15275718

Source:http://linkedlifedata.com/resource/pubmed/id/15275718

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0012634, umls-concept:C0013216, umls-concept:C0024881, umls-concept:C0030705, umls-concept:C0034897, umls-concept:C0035647, umls-concept:C0069515, umls-concept:C0242957, umls-concept:C0332293, umls-concept:C0442805, umls-concept:C0600558, umls-concept:C1522449
pubmed:issue	5
pubmed:dateCreated	2004-7-27
pubmed:abstractText	Preclinical data suggest that overexpression of Her2/neu confers cellular radioresistance. We retrospectively studied whether Her2/neu-positive disease was associated with locoregional recurrence (LRR) after postmastectomy radiotherapy (RT) for breast cancer.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7603616
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen
pubmed:status	MEDLINE
pubmed:month	Aug
pubmed:issn	0360-3016
pubmed:author	pubmed-author:BerryDonaldD, pubmed-author:BuchholzThomas ATA, pubmed-author:BuzdarAman UAU, pubmed-author:HortobagyiGabriel NGN, pubmed-author:HuangEugene HEH, pubmed-author:HuntKelly KKK, pubmed-author:KuererHenry MHM, pubmed-author:McNeeseMarsha DMD, pubmed-author:PerkinsGeorge HGH, pubmed-author:PusztaiLajosL, pubmed-author:SahinAysegul AAA, pubmed-author:SchechterNaomi RNR, pubmed-author:StromEric AEA, pubmed-author:ValeroVicenteV
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	59
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1337-42
pubmed:dateRevised	2009-11-19
pubmed:meshHeading	pubmed-meshheading:15275718-Adult, pubmed-meshheading:15275718-Antibiotics, Antineoplastic, pubmed-meshheading:15275718-Breast Neoplasms, pubmed-meshheading:15275718-Chemotherapy, Adjuvant, pubmed-meshheading:15275718-Clinical Trials as Topic, pubmed-meshheading:15275718-Confidence Intervals, pubmed-meshheading:15275718-Doxorubicin, pubmed-meshheading:15275718-Drug Resistance, Neoplasm, pubmed-meshheading:15275718-Female, pubmed-meshheading:15275718-Humans, pubmed-meshheading:15275718-Lymphatic Metastasis, pubmed-meshheading:15275718-Mastectomy, Radical, pubmed-meshheading:15275718-Neoadjuvant Therapy, pubmed-meshheading:15275718-Neoplasm Proteins, pubmed-meshheading:15275718-Neoplasm Recurrence, Local, pubmed-meshheading:15275718-Radiation Tolerance, pubmed-meshheading:15275718-Receptor, erbB-2, pubmed-meshheading:15275718-Receptors, Estrogen, pubmed-meshheading:15275718-Regression Analysis, pubmed-meshheading:15275718-Retrospective Studies
pubmed:year	2004
pubmed:articleTitle	Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy.
pubmed:affiliation	Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA. tbuchhol@mdanderson.org
pubmed:publicationType	Journal Article